Antioxidants Reveal Protection against the Biochemical Changes in Liver, Kidney and Blood Profiles after Clindamycin / Ibuprofen Administration in Dental Patients

Authors: Gouda K. Helal, Marwa I. Shabayek, Heba A. El-Ramly, Heba A. Awida

Abstract:

The adverse effects of Clindamycin (Clind.) / Ibuprofen (Ibu.) combination on liver, kidney, blood elements and the significances of antioxidants (N-acetylcysteine and Zinc) against these effects were evaluated. The study includes: Group I; control n=30, Group II; patients on Clind.300mg/Ibu.400mg twice daily for a week n=30, Group III; patients on Clind.300mg/Ibu.400mg+Nacetylcysteine 200mg twice daily for a week n=15 and Group IV; patients on Clind.300mg/Ibu.400mg+Zinc50mg twice daily for a week n=15. Serum malondialdehyde (MDA), alanine transferase (ALT), aspartate transferase (AST), γ glutamyl transferase (GGT), creatinine, blood urea nitrogen (BUN) were measured. Applying one way ANOVA followed by Tuckey Kramer post test, Group II showed significant increase in ALT, AST, GGT, BUN and decrease in Hb, RBCs, platelets than Group I. Group III showed significant decrease in ALT, AST, GGT, BUN than Group II. Moreover, Group IV showed significant decrease in ALT, AST, GGT and increase in Hb, RBCs, and platelets than Group II. Conclusively, Adding Zinc or Nacetylcysteine buffer the oxidative stress and improve the therapeutic outcome of Clindamycin/Ibuprofen combination.

Keywords: Clindamycin, Ibuprofen, Adverse effects, Antioxidant, Zinc, N-acetylcysteine.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1095997

References:

[1] L. Von Konow, C.E. Nord, A. Nordenram, Anaerobic bacteria in dentoalveolar infections, Int. J. Oral Surg. 10 (1981) 313-322.
[2] A.W. Chow, S.M. Rose, F.A. Brady, Orofacialodontogenic infections, Ann Intern. Med. 88 (1978) 392-402.
[3] L. Winter Jr., E. Bass, B. Recant, J.F. Cahaly, Analgesic activity of ibuprofen (Motrin) in postoperative oral surgery pain, Oral Surg. Oral Med. Oral Pathol. 45 (1978) 159-166.
[4] S. Sevillano, A.M. De la Mano, I. De Dios et al., Major pathological mechanisms of acute pancreatitis are prevented by N-acetylcysteine, Digestion 68 (2003) 34–40.
[5] I. Dalle-Donne, R. Rossi, R.D. Colombo et al., Biomarkers of oxidative damage in human disease, Clin. Chem. 52 (2006) 601–623.
[6] F. Santangelo, Intracellular thiol concentration modulating inflammatory response: influence on the regulation of cell functions through cysteine pro-drug approach, Curr. Med. Chem. 10 (2003) 2599-2610.
[7] E. Ristoff and A. Larsson, Inborn errors in the metabolism of glutathione, Orphanet, J. Rare Dis. 2 (2007) 16.
[8] M. Battino, M.S. Ferreiro, I. Gallardo, H.N. Newma, P. Bullon, The antioxidant capacity of saliva, J. Clin. Periodontol. 29 (2002) 189-194.
[9] E.M. Bulger and R.V. Maier, Antioxidants in critical illness, Arch. Surg. 136 (2001) 1201-1207.
[10] G.E. Sklar and M. Subramaniam, Acetylcysteine treatment for nonacetaminophen- induced acute liver failure, Ann Pharmacother. 38 (2004) 498-500.
[11] S. Holt, D. Goodier, R. Marley, D. Patch, A. Burroughs et al., Improvement in renal function in hepatorenal syndrome with Nacetylcysteine, Lancet 353 (1999) 294-295.
[12] L. Castro and B.A. Freeman, Reactive oxygen species in human health and disease, Nutrition 17 (2001) 161-165.
[13] M. Hatakeyama, M. Tsudo, S. Minamoto, T. Kono, T. Doi et al., Interleukin-2 receptor β chain gene: generation of three receptor forms by cloned human α and β chains cDNA's, Science 244 (1989) 551-556.
[14] K.I. Plaisance, G.L. Drusano, A. Forrest, R.J. Townsend, H.C. Standiford, Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate, Antimicrob. Agents Chemother. 33 (1989) 618- 620.
[15] D.C. Brater, C. Harris, J.S. Redfern, B.J. Gertz, Renal effects of COX-2- selective inhibitors, Am. J. Nephrol. 21 (2001) 1-15.
[16] M.R. Griffin, A. Yared, W.A. Ray, Non-steroidal anti-inflammatory drugs and acute renal failure in elderly persons, Am. J. Epidemiol. 151 (2000) 488-496.
[17] F.J. Taut, R. Breitkreutz, C.M. Zapletal, J.C. Thies, A. Babylon et al., Influence of N-acetylcysteine on hepatic amino acid metabolism in patients undergoing orthotropic liver transplantation, Transpl. Int. 14 (2001) 329-333.
[18] P.R. Grant, A. Black, N. Garcia, J. Prieto, J.A. Garson, Combination therapy with interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study, J. Med. Virol. 61 (2000) 439-442.
[19] O.V. Hein, R. Ohring, A. Schilling, M. Oellerich, V.W. Armstrong et al., N-acetylcysteine decreases lactate signal intensities in liver tissue and improves liver function in septic shock patients, as shown by magnetic resonance spectroscopy (2004). Extended case report Vol 8 No 2.
[20] M. Tepel and W. Zidek, N-Acetylcysteine in nephrology; contrast nephropathy and beyond, Curr. Opin. NephrolHypertens. 13 (2004) 649- 654.
[21] R. Safirstein, L. Andrade, J.M. Vieira, Acetylcysteine and nephrotoxic effects of radiographic contrast agents: A new use for an old drug, N. Engl. J. Med. 343 (2000) 210-212.
[22] M.J. Smilkstein, G.L. Knapp, K.W. Kulig, B.H. Rumack, Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985), N. Engl. J. Med. 319 (1988) 2557-2562.
[23] S.R. Powell, The antioxidant properties of zinc. J. Nutr. 130 (2000) 1447-1454.
[24] L. Allegra, M. Dal Sasso, C. Bovio, C. Massoni, E. Fonti, P.C. Braga, Human neutrophil oxidative bursts and their in vitro modulation by different N-acetylcysteine concentrations, Arzneimittelforschung 52 (2002) 669-676.
[25] F. Candan, F. Gultekin, F. Dandau, Effect of vitamin C and zinc on osmotic fragility and lipid peroxidation in zinc deficient hemodialysis patients. Cell Biochem. Funct. 20 (2002) 95-98.